[S,S]-Reboxetine Long Term Safety Study In Post-Shingles Pain.

Pfizer

Status and phase

Terminated

Phase 2

Conditions

Pain

Treatments

Drug: [S,S]-Reboxetine

Study type

Interventional

Funder types

Industry

Identifiers

NCT00354094

A6061030

Details and patient eligibility

About

The purpose of this study is to assess the long term (up to 2 years) safety and tolerability of [S,S]-Reboxetine in patients with pain after shingles.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients must have pain present for more than 3 months after healing of the shingles skin rash.
Patients at screening must have a score of >/=40mm on the pain visual analogue scale.

Exclusion criteria

Patients with significant hepatic impairment.
Patients with other severe pain, that may impair the self-assessment of pain due to postherpetic neuralgia (pain after shingles).